In last trading session, OncoCyte Corporation (NASDAQ:OCX) saw 0.12 million shares changing hands with its beta currently measuring 1.63. Company’s recent per share price level of $0.48 trading at $0.03 or 5.78% at ring of the bell on the day assigns it a market valuation of $54.74M. That closing price of OCX’s stock is at a discount of -462.5% from its 52-week high price of $2.70 and is indicating a premium of 27.08% from its 52-week low price of $0.35. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.69 million shares which gives us an average trading volume of 388.69K if we extend that period to 3-months.
OncoCyte Corporation (NASDAQ:OCX) trade information
Upright in the green during last session for gaining 5.78%, in the last five days OCX remained trading in the green while hitting it’s week-highest on Wednesday, 11/23/22 when the stock touched $0.48 price level. OncoCyte Corporation’s shares saw a change of -78.06% in year-to-date performance and have moved 22.97% in past 5-day. OncoCyte Corporation (NASDAQ:OCX) showed a performance of -38.86% in past 30-days. Number of shares sold short was 2.58 million shares which calculate 13.41 days to cover the short interests.
OncoCyte Corporation (OCX) estimates and forecasts
Statistics highlight that OncoCyte Corporation is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -51.44% of value to its shares in past 6 months, showing an annual growth rate of -25.00% while that of industry is 3.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 26.70% in the current quarter and calculating 16.70% increase in the next quarter. This year revenue growth is estimated to fall -9.30% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $1.48 million for the same. And 6 analysts are in estimates of company making revenue of $2.03 million in the next quarter that will end on Dec 2022.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -11.40% during past 5 years.
OncoCyte Corporation is more likely to be releasing its next quarterly report on November 10 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
OncoCyte Corporation (NASDAQ:OCX)’s Major holders
Insiders are in possession of 4.64% of company’s total shares while institution are holding 67.53 percent of that, with stock having share float percentage of 70.81%. Investors also watch the number of corporate investors in a company very closely, which is 67.53% institutions for OncoCyte Corporation that are currently holding shares of the company. Broadwood Capital, Inc. is the top institutional holder at OCX for having 23.35 million shares of worth $21.01 million. And as of Jun 29, 2022, it was holding 19.69% of the company’s outstanding shares.
The second largest institutional holder is Pura Vida Investments, LLC, which was holding about 18.06 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 15.22% of outstanding shares, having a total worth of $16.25 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 3.08 million shares of worth $2.77 million or 2.60% of the total outstanding shares. The later fund manager was in possession of 1.09 million shares on Jun 29, 2022, making its stake of worth around $0.98 million in the company or a holder of 0.92% of company’s stock.